Brought to you by 
Editas partners with Juno to create new CAR/TCR therapies; Programs opted
01 Feb 2023
Executive Summary
Editas Medicine Inc. and Juno Therapeutics Inc. joined forces in an exclusive collaboration that sees the partners combining Editas’ disruptive genome editing technologies with Juno’s chimeric antigen receptor (CAR) and T-cell receptor (TCR) immunotherapies to work on three new research programs in cancer.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Technologies
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Editas partners with Juno to create new CAR/TCR therapies; Programs opted
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice